- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02378571
Medication Adherence Telemonitoring to Reduce Heart Failure Readmissions (TEAM-HF)
18. januar 2018 opdateret af: Ian Kronish, Columbia University
Telemonitoring Adherence to Medications to Reduce Heart Failure Readmissions: A Pilot Randomized Clinical Trial
The overall purpose of this project is to determine the feasibility of conducting a large scale randomized clinical trial that compares remote monitoring of adherence to loop diuretics using a wireless electronic pillcap with usual care among recently hospitalized heart failure patients.
The long-term goal of this program of research is to determine the effect of the adherence telemonitoring intervention on medication adherence and hospital readmissions among recently hospitalized heart failure patients.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Approximately one in four patients hospitalized with heart failure is readmitted within 30 days of discharge and more than 50% are readmitted within 6 months of discharge.
Heart failure admissions are a major contributor to the enormous health care costs associated with heart failure.
Thus far, the identification of effective interventions that prevent unnecessary readmissions has remained elusive.
As a result, there is a pressing need to identify novel, cost-effective approaches to reducing heart failure readmissions.
A growing body of research suggests that poor adherence to heart failure medications is a major reason for preventable heart failure readmissions.
In particular, loop diuretic medications are essential to preventing the cardiopulmonary system from becoming overloaded.
Patients who have been recently hospitalized may be especially vulnerable to adherence problems as a result of the stress of the recent hospitalization which commonly induces sleep deprivation, nutritional deficiency, physical deconditioning, cognitive impairment, and even delirium.
Recent advances in wireless health now enable us to remotely, unobtrusively, and objectively monitor adherence to heart failure medications in the post-discharge period.
Early identification of non-adherence to loop diuretic medications has the prevention to prevent a volume overloaded state that leads to a heart failure readmission.
As patients who are non-adherent to their loop diuretics may also be non-adherent to other recommended self-management behaviors, early identification of medication nonadherence may provide the context to identify other gaps in self-management.
To test our hypothesis that it is feasible to conduct a randomized trial of wireless, medication adherence monitoring with feedback to patients and clinicians, the investigators will enroll 40 patients who are hospitalized for heart failure and discharged on a diuretic medication.
Patients will be randomized to 1) usual heart failure care + telemonitoring adherence to diuretic medications (INT); N=20 or 2) usual heart failure care (CTR); N=20.
All patients will be asked to take their diuretic medication from a standard pill bottle covered by an electronic pill cap (GlowCap), but only patients assigned to the intervention arm will have their adherence telemonitored by a study clinician in real-time.
Patients will have their adherence to medications measured in this fashion for 30 days after discharge.
Patients will be contacted at 30 days to determine if they have been hospitalized and to collect other self-reported outcomes data.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
40
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Columbia University Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Hospitalized for heart failure
- Prescribed loop diuretic medication at discharge
Exclusion Criteria:
- Age less than 21 years
- New York Heart Association Class IV heart failure
- Terminal illness (<6 mo prognosis)
- Unable to self-administer medications due to mental illness or cognitive impairment
- Non-English/Spanish speaking
- Discharged to an institutional setting (e.g., nursing home)
- Cardiologist or primary care provider refusal
- Unavailable for follow-up
- No access to telephone
- Enrolled in another cardiac trial
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Ingen indgriben: Usual care
Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes.
This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later.
Participants will not be provided with any advice on heart failure adherence.
|
|
Eksperimentel: Medication adherence telemonitoring
At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician.
A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis.
The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care.
Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
|
The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care.
Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of days participants take the correct number of doses of their diuretic
Tidsramme: 30 days post-discharge
|
Loop diuretic adherence: Adherence to the diuretic medication will be electronically measured using GlowCaps (Vitality Inc.) in the 30 days after hospitalization.
Medication adherence will be calculated as the percent of days participants take the correct number of doses of their diuretic.
Days when participants are incapable of taking their medication from the GlowCap bottle (e.g., while hospitalized) will be censored from calculations.
|
30 days post-discharge
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Score on the Self Care Heart Failure Index
Tidsramme: 30 days post-discharge
|
Heart Failure Symptoms, Self-Efficacy for self-managing heart failure, and Self-Management Behaviors will be measured using Self Care Heart Failure Index
|
30 days post-discharge
|
Proportion very or extremely satisfied with heart failure care
Tidsramme: 30 days post-discharge
|
Satisfaction with Heart Failure Care will be assessed by asking participants "Overall, how satisfied are you with the care you have been receiving for your heart problems over the last 30 days?" Response options will include: "not at all satisfied", "a little satisfied", "very satisfied," and "extremely satisfied."
|
30 days post-discharge
|
Number of readmissions and emergency room visits
Tidsramme: 30 days post-discharge
|
Readmissions and emergency room visits will be assessed by contacting participants or their close contacts at 30 days.
Hospital records will be reviewed to confirm readmissions, to determine the reason for readmission or emergency room visit (heart failure versus other), and to determine whether it was related to medication nonadherence.
|
30 days post-discharge
|
Proportion attending at least 1 scheduled outpatient clinic visit within 30 days of discharge
Tidsramme: 30 days post-discharge
|
Attendance at scheduled outpatient clinic visits will be assessed by contacting participants or their close contacts at 30 days.
Hospital records will be reviewed, when available, to determine whether and how medication adherence was addressed during the visit.
|
30 days post-discharge
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Ian M Kronish, MD, MPH, Columbia University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2014
Primær færdiggørelse (Faktiske)
1. oktober 2015
Studieafslutning (Faktiske)
1. november 2015
Datoer for studieregistrering
Først indsendt
27. februar 2015
Først indsendt, der opfyldte QC-kriterier
3. marts 2015
Først opslået (Skøn)
4. marts 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
23. januar 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
18. januar 2018
Sidst verificeret
1. januar 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- AAAO3305
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hjertefejl
-
Region SkaneTilmelding efter invitationHjertesvigt New York Heart Association (NYHA) klasse II | Hjertesvigt New York Heart Association (NYHA) klasse IIISverige
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... og andre samarbejdspartnereIkke rekrutterer endnuHjertesvigt, systolisk | Hjertesvigt med reduceret udstødningsfraktion | Hjertesvigt New York Heart Association Klasse IV | Hjertesvigt New York Heart Association Klasse IIIPolen
-
University of WashingtonAmerican Heart AssociationAfsluttetHjertesvigt, Kongestiv | Mitokondriel ændring | Hjertesvigt New York Heart Association Klasse IVForenede Stater
-
Novartis PharmaceuticalsAfsluttetPatienter, der med succes afslutter den 12-måneders behandlingsperiode i kernestudiet (de Novo Heart-modtagere), som var interesserede i at blive behandlet med EC-MPS
-
University Hospital, GasthuisbergUkendtTransient Left Ventricular Ballooning SyndromeBelgien
-
NYU Langone HealthRekrutteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeForenede Stater
-
French Cardiology SocietyAfsluttet
Kliniske forsøg med Medication adherence telemonitoring
-
Erasme University HospitalCentre Hospitalier Régional de la CitadelleIkke rekrutterer endnuÅndedrætsinsufficiens, der kræver mekanisk ventilationBelgien
-
University Health Network, TorontoUniversity of Toronto; Aga Khan University; Jinnah Postgraduate Medical CentreIkke rekrutterer endnuPræeklampsi | Gravid med komplikationer
-
University of AlbertaRekruttering
-
Universidad Nacional de TucumanAfsluttet
-
humanITcareRekrutteringHjertefejl | Kroniske patienterSpanien
-
Georg Nilius, Prof DR medHeinen und Löwenstein GmbH & Co. KGRekrutteringKronisk obstruktiv lungesygdomTyskland
-
Imperial College LondonHoneywell HomMedAfsluttetHjertefejlDet Forenede Kongerige
-
Fundación Pública Andaluza Progreso y SaludTelefónica S.A.; Agency of Social Services and Dependency of Andalusia; Salud...UkendtKronisk lungesygdom | Kronisk hjertesygdomSpanien
-
University Hospital, MontpellierADENE, Montpellier; AGIR à dom, Meylan; ASTEN sante, Pays de la Loire; ELIA...Rekruttering
-
University of North Carolina, Chapel HillMedical University of South Carolina; National Institute of Mental Health... og andre samarbejdspartnereAfsluttetHIV/AIDS | Medicinadhærens | Hiv | Seksuel adfærd | Seksuelt overførte infektioner (ikke hiv eller hepatitis)Forenede Stater